# Advancing Tobacco Control Practice through Policy Evaluation: Engaging Stakeholders to Set an Agenda for Reducing Tobacco Industry Influence

Erika Fulmer, MHA Evaluation Team

CDC Office on Smoking and Health
Evaluation 2011
Anaheim, California, November 3, 2011


The findings and conclusions in this presentation are those of the author and do not necessarily represent the views of the Centers for Disease Control and Prevention.

## Historic Policy Opportunities in Tobacco Control



Courtesy of Campaign for Tobacco Free Kids

## The National Policy Environment



## **OSH Background**

### Office on Smoking and Health (OSH):

- Develop, conduct, and support strategic efforts to protect the public's health from the harmful effects of tobacco use.
- Fund health departments in all 50 states, the District of Columbia, and seven U.S. territories for comprehensive tobacco prevention and control.
- Funded programs focus on tobacco use prevention, cessation, smoke-free environments, and tobaccorelated disparities.

## OSH Tobacco Industry Monitoring Summit

An approach for capturing expert opinion

## Summit Purpose

To capitalize on opportunities presented by the Family Smoking Prevention and Tobacco Control Act, OSH is working to clarify its strategic priorities in the new environment and to enhance and create effective monitoring systems that will inform program and policy efforts.

#### Key issues:

- Clarify areas critical to reducing tobacco industry influences
- Inform possible development of appropriate surveillance and evaluation approaches

### Clusters and Focus Areas



Photo courtes y of Campaign for Tobacco Free Kids

## Advertising

- Retail advertising
- New and other tobacco products
- Electronic media forums



## **Pricing**

- Price discounts and bonus cigarettes
- Retail slotting and trade allowances

### Clusters and Focus Areas



Photo courtesy of tobacco 21.org

## Impact on the Consumer

- Survey-based measurement issues at National and State levels
- Tobacco related attitudes and use



## Impact on the Public

- Tobacco industry interference
- Lobbying, contributions and corporate social responsibility
- Sponsorship

## Clusters and Focus Areas



## Retail Distribution

- Store type, number, density
- Retailer licensing

Photo courtesy of Store Alert.org




## Alternative Distribution

- Tax evasion and counterfeit
- Internet sales of tobacco

## Considering Stakeholder Input: Prioritizing Recommendations

#### TI Monitoring Summit Findings

- Advertising
- Pricing
- Impact on consumer
- Impact on public
- Retail distribution
- Alternative distribution



## Recommendation Profile


#### ADVERTISING- New and other tobacco products

AN1 Develop a retail monitoring system for new tobacco products			
Description	Monitor trade journals (i.e. National Association of Convenience Stores) and company websites to learn about new products and identifying places where early product launches are occurring.     Engage and mobilize communities with a network of data collectors to collect information on new products when needed.		
Relevant Indicator(s)	To be determined		
Monitoring level	Nationa ☑	I State	Local
Why this is important	Monitoring of new and other tobacco products is important to check compliance with regulations and provide data to support policy initiatives. Internal industry documents outline the increasing importance of the development of new smokeless tobacco products to offset smoking reductions due to clean indoor air policy restrictions, either as substitute or dual-use products. <sup>1</sup>		
Alignment with OSH strategic priorities	<ul> <li>Healthy People 2020</li> <li>MAPPS Strategies (Point of purchase/promotions) being implemented by state and local CPPW grantees</li> </ul>		
Potential impact	Impacts of this monitoring system should be considered in light of the overall morbidity and mortality caused by new and other tobacco products versus cigarettes. Monitoring of new and other tobacco products provides information for advocacy and counter-marketing campaigns as well as the evaluation of local, state and national policies. It could also enhance enforcement efforts by identifying products released by small manufacturers who release directly to the public instead of going through FDA review.		
Longevity and timeliness	Currently Salient	Long-term Need ☑	FDA regulations addressing the retail environment and new tobacco products may impact the long-term need for such a system
Feasibility	CDC should consider partnering with another agency to implement this monitoring system (i.e. NCI through the TSEEN, "New Product Watch).		
Comments	Suggest     o     o     o     o     o	ted elements to include in the syst New and other tobacco products Advertising, Availability of products Type and extent of health claims Target population	types,
OVERALL RATING	High	CDC ROLE	Primary Supporting ☑ □


## Considering Stakeholder Input: Prioritizing Recommendations

#### TI Monitoring Summit Findings

- Advertising
- Pricing
- Impact on consumer
- Impact on public
- Retail distribution
- Alternative distribution




## Key Outcome Indicators for Evaluating Comprehensive Tobacco Control Programs




- Main purpose is to assist state and territorial tobacco control program evaluation efforts under the National Tobacco Control Program (NTCP)
- Primary Audiences
  - Planners, managers, and evaluators of state programs
  - CDC's national partners
- Released in 2005

#### Preventing Initiation of Tobacco Use Among Young People



## Indicator Rating Table



- Overall quality
- Strength of the evaluation evidence
- Intensity of resources to collect and analyze data
- Utility of indicator to answer key evaluation questions
- Face validity of indicator
- Accepted practice

## Considering Stakeholder Input: Updating Key Outcome Indicators (KOI)

2005 KOI Guide Goal Area 1: Preventing Initiation

**TI Monitoring** Recommendations

**Full Expert** Small Group **Review** Review **Engage Small Engage Full** Group of Revised Revised **Expert** Full List of External Logic Model Review Panel Listof **Indicators Experts** and Draft Candidate with Listof Indicator **Indicators Indicators** Ratings w/ Profiles Engage OSH **OSH** Content **Review Experts** Final GOALAREA 1 Materials Updated logic model

- **Updated indicators**
- Updated profiles with ratings

## Key Takeaways

## Implementing effective evaluation systems requires a stakeholder driven, multidisciplinary approach:

- Build replicable methods for capturing stakeholder input into the process
- Consider the best form, content and mode for capturing stakeholder input
- Apply consistent assessment criteria to enhance transparency

Building evaluation capacity takes ongoing commitment and a willingness to reassess one's approach

## **Special Thanks**

#### CDC:

- Kimberly Snyder
- Marti Engstrom
- Shanta Dube
- Sarah Cercone

RTI, International:

Todd Rogers

### References

Cruz TB. Monitoring the tobacco use epidemic IV. The vector: Tobacco industry data sources and recommendations for research and evaluation. *Prev Med* 48 (2009) S24–S34.

Eckhart, D., Tobacco Control Legal Consortium, *The Tobacco Master Settlement Agreement: Enforcement of Marketing Restrictions* (2004).

The National Center for Tobacco Free Kids. The Supreme Court FDA Ruling: That Congress has not yet provided FDA with Authority over Tobacco Products. (2001).

Starr G, Rogers T, Schooley M, Porter S, Wiesen E, Jamison N. *Key Outcome Indicators for Evaluating Comprehensive Tobacco Control Programs*. Atlanta, GA: Centers for Disease Control and Prevention (2005).

www.cdc.gov/tobacco/tobacco\_control\_programs/surveillance\_evaluation/key\_out come/index.htm

Tobacco Legal Consortium, Federal Regulation of Tobacco: Impact on State and Local Authority (2009).

Tobacco Legal Consortium, Federal Regulation of Tobacco: A Summary (2009).

### **Questions?**



**Contact Information:** 

Erika Fulmer at <a href="mailto:EFulmer@cdc.gov">EFulmer@cdc.gov</a>

The findings and conclusions in this presentation are those of the author and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

SAFER • HEALTHIER • PEOPLE™

## Thank you

For more information please contact Centers for Disease Control and Prevention

1600 Clifton Road NE, Atlanta, GA 30333

Telephone, 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348

E-mail: cdcinfo@cdc.gov Web: www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

